Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Randomized, Open-Label, Crossover, Single Oral Dose Study to Assess the Bioequivalence of LAF237 Tablet Manufactured by Beijing Novartis Pharma Ltd. to Imported LAF237 Tablet in Chinese Healthy Subjects

NCT00414947 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00414947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00414947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Randomized, Open-Label, Crossover, Single Oral Dose Study to Assess the Bioequivalence of LAF237 Tablet Manufactured by Beijing Novartis Pharma Ltd. to Imported LAF237 Tablet in Chinese Healthy Subjects
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2006
Completion date
Not reported
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy